Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Yellowstone Biosciences

Request full access

Soluble bispecific TCR-based therapies for oncology

Oxford, United KingdomFounded 2023Biotech & Life Sciences

About Yellowstone Biosciences

Yellowstone Biosciences is a biotechnology company that spun out of the University of Oxford in June 2024, pioneering a new class of cancer therapies. The company was founded by Professor Paresh Vyas and Julian Hirst. It is built upon two decades of Professor Vyas's research at the University of Oxford, where he serves as Professor of Haematology and is a practicing clinician with a focus on acute myeloid leukaemia (AML). His research has led to the creation of a proprietary biobank with over 10,000 samples from more than 3,000 AML patients, which has been instrumental in identifying a new class of therapeutically targetable antigens. Julian Hirst, the Co-founder and CFO, has over 20 years of experience in investment banking and biotechnology, including roles at Immunocore and MiroBio.

The company launched with a £16.5 million Series A financing from Syncona, a FTSE 250 life sciences investor, which holds a majority stake. This funding is intended to support the company's operational setup, advance its lead program, and explore pipeline expansion. Yellowstone's core technology focuses on developing soluble bispecific T-cell receptor (TCR)-based therapies targeting human leukocyte antigen (HLA) Class II molecules on cancer cells. This approach is designed to selectively kill tumor cells while sparing healthy ones. The company's business model is centered on the research and development of these novel cancer treatments. By leveraging its proprietary biobank and protein engineering capabilities, Yellowstone aims to create therapeutic T-cell bispecific molecules.

The initial focus is on its lead program in AML, a type of leukemia with a high mortality rate and limited standard care options for most patients. Beyond AML, the company's technology has potential applications across a range of common solid tumors that express HLA-II, including ovarian, non-small cell lung, colorectal, prostate, breast, and renal cancers, as well as melanoma. Headquartered in Oxford, UK, Yellowstone operates from a dedicated lab and office space at ARC Oxford, a life sciences cluster.

Source: Dealroom company data

At a glance

Status
Operational
Employees
28
Open positions
1
Dealroom signal
81.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, DT and LS, uk is8 life sciences, UKSU, UKSU2010, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jun 2024 $22M $87M Syncona ↗
SPINOUT✓Other financing Jan 2023 $0 — University of Oxford ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Yellowstone Biosciences website traffic

Latest recorded traffic for Yellowstone Biosciences is 1.5K monthly website visits, up 167.9% over the last three months. Yellowstone Biosciences's team grew 33.3% over the past year.

Latest monthly visits1.5K 3-month web change+167.9% 1-year team growth+33.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Yellowstone Biosciences in the Oxford ecosystem

Live from Dealroom

The Yellowstone Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Syncona

Other known investors3 additional known investors

  • University of Oxford
  • OUI Startup Incubator
  • Oxford University Innovation
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇬🇧 United Kingdom100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Yellowstone Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Yellowstone Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.